Today: 10 November 2025
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stocks Rocket on Cooling Inflation Data; Tech Stocks & Fed Speeches in Spotlight

Stocks Rocket on Cooling Inflation Data; Tech Stocks & Fed Speeches in Spotlight

Markets Rally as US Inflation Cools Wall Street surged on Oct. 24 after data showed US consumer prices rose less than forecast. The Labor Department’s CPI for September came in at 3.0% year-on-year (3.0% core) vs 3.1% expected xtb.com. That miss drove a rally in stock futures and sent the US dollar slightly lower, while gold and bonds rallied on renewed rate-cut hopes xtb.com reuters.com. As Reuters notes, the dollar index was steady (around 99.06) ahead of the report reuters.com, and traders now fully price a quarter-point Fed cut next week reuters.com reuters.com. “In midday trading, futures on the S&P 500
24 October 2025
 ·  ·  ·  ·  · 
Retirement Alert: 90% of Americans Are Giving Up Big Social Security Checks (Act Now Before It’s Too Late!)

Retirement Alert: 90% of Americans Are Giving Up Big Social Security Checks (Act Now Before It’s Too Late!)

In short, most retirees are stuck in a cash crunch. They need the income now, even though postponing Social Security would boost their checks permanently housingwire.com cbsnews.com. A survey by Schroders (released Oct. 22, 2025) found 37% say they’ll claim early simply to get money sooner, while 36% fear the program might run out housingwire.com. Deb Boyden (Schroders’ head of U.S. retirement) warns that many Americans are anxious about solvency “and yet so few are willing to hold off” taking benefits housingwire.com cbsnews.com. In other words, fears of a social security crash and living paycheck-to-paycheck have outweighed the math: waiting
24 October 2025
 ·  ·  ·  · 
Stocks Rally as U.S. Inflation Cools – Asia Joins Global Rally, Fed Cut Seen as Lock

Stocks Rally as U.S. Inflation Cools – Asia Joins Global Rally, Fed Cut Seen as Lock

Market Analysis: Friday’s tame CPI print soothed immediate rate-cut concerns and spurred a relief rally. Futures lifted all sectors, but tech/AI remains a focus. For example, AMD is near $235 after surging ~80% YTD on AI demand ts2.tech, and TSMC hovers near all-time highs (~$294) on chip demand ts2.tech. Mega-cap favorites carry “strong buy” sentiment – Microsoft, Amazon, Walmart and Broadcom top analyst picks ts2.tech. Health and energy also shine: Eli Lilly (~$935) is up on obesity-drug sales (analysts see ~20% more upside) ts2.tech, while refiners benefit from resilient oil prices. Expert Voices: “Valuations continue to be the best argument
24 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Billionaire Larry Ellison’s Fortune Plummets: Oracle Share Slump Wipes Out $24B

Billionaire Larry Ellison’s Fortune Plummets: Oracle Share Slump Wipes Out $24B

Stock Slide Hits Ellison’s Fortune Oracle’s spectacular AI-driven rally has turned choppy in recent days. After rocketing to all-time highs in September (briefly valuing Ellison’s stake at ~$393 B) reuters.com, profit-taking set in. The stock plunged about 7% on Oct. 17 (wiping ~$24B off Ellison’s wealth) and sank nearly 5% on Oct. 20 (erasing another ~$14B) financialexpress.com financialexpress.com. The selloff reflects a shift from “euphoria to caution,” as investors booked gains after Oracle’s string of AI contract announcements. By Oct. 23, ORCL closed around $280 ts2.tech – still roughly 70% above its January price, but down from its Sept. peak (~$345). Market watchers describe
24 October 2025
 ·  ·  ·  ·  · 
P&G Earnings Smash Estimates – Beauty Boom and Razors Fly Off Shelves in Q1

P&G Earnings Smash Estimates – Beauty Boom and Razors Fly Off Shelves in Q1

Procter & Gamble’s Q1 report beat expectations across the board. Revenue of $22.39 billion (vs. ~$22.17B forecast) and core EPS of $1.99 (vs. $1.90) both topped consensus marketscreener.com. In a statement, P&G credited resilient consumer demand for premium brands. For example, its beauty brands (Pantene, Olay, etc.) delivered roughly 6% organic growth finimize.com – a bright spot after weaker quarters. Grooming and personal care also held up; Bloomberg reports shoppers “brushed off price increases and snapped up the company’s Gillette razors and Secret deodorant,” underpinning the beat bloomberg.com. Overall volumes were flat, but higher pricing and cost savings boosted results.
24 October 2025
 ·  ·  ·  · 
Social Security COLA 2026: The Raise EVERYONE Is Talking About — And Why It Might Fall Short

Social Security COLA 2026: The Raise EVERYONE Is Talking About — And Why It Might Fall Short

Why the COLA Announcement Was Delayed Normally the SSA announces the annual COLA in mid-October after the Bureau of Labor Statistics releases the September Consumer Price Index for Urban Wage Earners (CPI-W). The COLA is based on the rise in average CPI-W over July–September vs. the same period a year earlier cbsnews.com. Because of the federal government shutdown, the BLS delayed the CPI release to Oct. 24, and the SSA said it will announce the 2026 COLA on Oct. 24 as well cbsnews.com cbsnews.com. In other words, this Friday should be the big day for Social Security. Until the numbers
24 October 2025
 ·  ·  ·  · 
Microsoft Stock Soars on AI and Cloud Frenzy – Analysts Eye $600+ Price Targets

Microsoft Stock Soars on AI and Cloud Frenzy – Analysts Eye $600+ Price Targets

Cloud and AI Drive Momentum Microsoft’s Azure cloud has been the standout. In FY2025 Azure revenue surpassed $75B, growing ~34% ts2.tech ts2.tech. Analysts note Azure continues to accelerate: in Q4 it was up ~39%, handily beating AWS and Google Cloud ts2.tech. That dominance is a key reason for the stock’s rally. As TechStock² (TS2.Tech) reports, Wall Street “still sees $600–$650 [over 12 months]” for MSFT ts2.tech. Indeed, banks like UBS and Bank of America recently reiterated Buy ratings and raised targets to ~$650 and $640, respectively insidermonkey.com ts2.tech. UBS “highlighted accelerating Azure growth trends” in its $650 target insidermonkey.com, and
24 October 2025
 ·  ·  ·  ·  · 
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

As of Oct 24, 2025, RVPH shares trade around $0.57 investing.com, after a volatile October run (ranging roughly $0.26–$0.84). The stock has surged ~28% on Oct 23 (to $0.5675 markets.financialcontent.com) after a prior drop (–23% on Oct 8 benzinga.com). Recent catalysts include completion of a 1-year Phase 3 trial (brilaroxazine OLE) showing robust, sustained efficacy revivapharma.com, and plans for an FDA meeting in Q4 2025 toward a 2026 NDA revivapharma.com. Reviva also raised capital via equity offerings (~$10M in Q2 and ~$9M in Sept revivapharma.com revivapharma.com) to fund its CNS pipeline. Analysts remain extremely bullish – consensus is “Strong Buy”
24 October 2025
 ·  ·  ·  ·  · 
AMD Stock Skyrockets on AI Mega-Deals – Is $300 Next?

AMD Stock Skyrockets on AI Mega-Deals – Is $300 Next?

In summary, AMD’s recent AI-driven surge has been fueled by heavyweight partnerships and robust demand, earning plaudits from executives and analysts alike. But the stock now sits at lofty valuations. Investors will be watching closely whether AMD can translate its new AI wins into sustained growth – success could justify prices well above today’s $235, while any misstep might curb the rally. As one analyst quipped, AMD is striving to be the “open, secure, and scalable” AI platform versus Nvidia’s closed box ts2.tech. Whether Wall Street’s bullish forecasts come true will depend on that bet paying off in the years
24 October 2025
 ·  ·  ·  ·  · 
Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta’s Oct. 24 announcement ignited optimism. According to the official press release, Anemocyte will incorporate Genenta’s clinically validated LVV plasmid DNA platform (originating from Naldini’s research) into its production pipeline investing.com. “By making our clinically validated LVV plasmid DNA technology platform available to Anemocyte and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry,” said CEO Pierluigi Paracchi investing.com. Anemocyte’s CEO Marco Ferrari added that the deal ensures customers have access to “a robust, well-established platform” for cutting-edge cell therapies investing.com. In effect, the partnership helps Genenta and its clients secure
24 October 2025
 ·  ·  ·  ·  · 
Plug Power (PLUG) Stock Skyrockets 170% on Hydrogen Hype – Can It Last?

Plug Power (PLUG) Stock Skyrockets 170% on Hydrogen Hype – Can It Last?

Stock Performance and Volatility Plug Power’s share price has been on a roller-coaster. After languishing around $1.50 in late summer 2025, the stock surged to a new 52-week high near $4.58 in early October marketbeat.com ts2.tech. By Oct. 23 it was trading around $2.88 marketbeat.com – still roughly double its summer lows. This sharp rise (≈170% in ~3 months ts2.tech) was driven partly by a classic short squeeze: nearly one-third of Plug’s float was sold short, forcing many bears to cover as positive news hit ts2.tech. Trading volume exploded on rally days (often 2–3× normal levels), reflecting feverish buying. In
24 October 2025
 ·  ·  ·  ·  · 
Ambev Stock Rallies to $2.21 – Analysts Pour Cold Water on Rally

Ambev Stock Rallies to $2.21 – Analysts Pour Cold Water on Rally

Market Snapshot: In recent days Ambev stock has been flat-to-up (≈+0.5%). On Oct 24 it traded near $2.20 reuters.com, close to its recent five-week low (~$2.18) and well below its 52-week high ($2.63). Year-to-date returns are modest (roughly +6–8%) reuters.com. Volumes have picked up ahead of Q3 earnings and on broader market swings. The slight uptick Oct 24 followed a series of choppy sessions, suggesting investors are watching for catalysts. Recent Developments: No major company-specific news broke in the past week. The focus is squarely on Ambev’s business trends and upcoming Q3 release (Oct 30). Q2 results (July 31) showed
24 October 2025
 ·  ·  ·  ·  · 
1 … 46 47 48 49 50 … 175
Go toTop